Tag: Amplatzer Amulet
TCT 2022: Amulet occluder keeps pace with Watchman at three years
Long-term follow-up of patients with non-valvular atrial fibrillation (AF) receiving the Amplatzer Amulet left atrial appendage occlusion (LAAO) device have shown continued safety and...
PCR e-Course 2020: Roll-in trial finds high device success rate for...
Left atrial appendage occlusion (LAAO) using the Amplatzer Amulet (Abbott) device has a high implant success rate and a low procedural complication rate in...
PCR e-Course 2020: Left atrial appendage occlusion improves clinical outcomes versus...
Left atrial appendage occlusion (LAAO) improves clinical outcomes including ischaemic stroke, major bleeding and all-cause mortality, in atrial fibrillation (AF) patients with a high...
Abbott announces trial to assess new therapy option for stroke
Abbott has announced approval from the US Food and Drug Administration (FDA) for the CATALYST trial to examine its Amplatzer Amulet device compared to...
AF Symposium 2017: Use of intracardiac echocardiography is a “viable option”...
Intracardiac echocardiograpy (ICE) facilitates a high success implant rate of the Amplatzer Amulet left atrial appendage (LAA) occluder (St Jude Medical/Abbott) as well as...
Amulet study shows high implant success rates with Amplatzer Amulet LAA...
A study presented at the last late-breaking trial session of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington, DC, USA) indicates...
St Jude Medical launches trial of Amplatzer Amulet left atrial appendage...
The St Jude Medical Amplatzer Amulet Investigational Device Exemption (IDE) trial, which will evaluate the safety and effectiveness of the company’s Amplatzer Amulet left...